patients with widely varied prognoses identified as follows:
(1) those with a WBC count <50 x 1 0 3 /~L who lacked massive splenomegaly and had blasts expressing CD5 had the best prognosis (66%, SE = 7%. EFS 4 years, n = 84):
(2) those with ( b l ) WBC counts <50 x 103/pL with either massive splenomegaly or who had blasts lacking CD5 expression, or (b2) WBC counts =.50 x 103/pL with expression of the THY antigen had an intermediate prognosis (39%. SE = 7% EFS at 4 years, n = 94); (3) those with WBC counts >50 x 103/pL and whose blasts lacked expression of THY antigen had the poorest outcome (EFS = 19% at 4 years, SE = 8%. n = 63). A three-way comparison of EFS according t o these groupings showed significant differences among the three patient groups (P < .001). The recursive partitioning was able t o classify 241 (95%) of the patients. Twelve patients could not be grouped because of missing data. We conclude that this prognostic factor analysis provides information of potential importance for design of randomized clinical trials for children with T-cell ALL (T-ALL), because appropriate stratification depends on results of such analysis t o ensure comparability of patient groups. In this study, recursive partitioning analysis provides prognostic insight that was not obtained by the stepwise Cox regression method. However, these results should be considered tentative until confirmed in a prospective clinical trial. children with T-ALL who have different clinical and biologic features at diagnosis. Appropriate studies have been performed in children with B-cell progenitor malignancies during the past 10 years, and have provided important information regarding the prognostic strength of these features (white blood cell [WBC] level, age, gender, stage of cell differentiation, genetic features, etc). 1-4,6-10 Information from these studies has been valuable in improving the comparability of patient groups for clinical trials. Also, the identification of groups of children with widely different prognoses has led to tailored therapy designed to improve the therapeutic index.
In part to address this need for information regarding estimated prognosis in subgroups of children with T-ALL, the Pediatric Oncology Group (POG) treated a relatively large group (n = 253) of children registered between May 1981 and January 1986 with serologically well-defined T-ALL uniformly on therapy modeled after the LSA,L,.".'* Retrospective analysis of clinical and biologic features of these children has provided important new information regarding prognostic factors in T-ALL and forms the basis for this report.
MATERIALS AND METHODS

Patients and treatment.
Bone marrow samples from all untreated patients with ALL (n = 2,022) entered on the POG classification protocol (POG 8035) were sent to reference laboratories of the POG for immunologic marker studies to define the major immunophenotypes of ALL (early pre-B, pre-B, T, and B cell) using previously published For 496 patients with ALL, cell
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marker assessment was not adequate to permit definitive assignment to a pre-B, B, T or early pre-B group (see Definitions section); hence, these subjects were excluded from this analysis, leaving 1,526 with adequate marker studies for further consideration. With the exception of children enrolled in pilot studies, all patients with non-B, non-T-ALL were entered on POG treatment protocols according to immunophenotype ( B T; or non-B, non-T). Two hundred fifty-three eligible children had T-ALL and were treated uniformly on POG 7837 (Fig 1) . General details of this treatment regimen have, for the most part, been previously published." However, further modifications were made in this study as detailed in Fig 1. Informed consent was obtained from parents, patients, or both, as deemed appropriate for both treatment and laboratory studies. In summary, 253 patients were used in the analysis, with 192 having complete data on all covariates. Leukemic cells were examined morphologically to establish the diagnosis of acute leukemia. In addition, cells were examined for cytochemical reactivity to Sudan black B and nonspecific esterase to exclude myeloid leukemia. Sheep erythrocyte receptors were also assayed with use of established and , and HLA-DR) as previously described.''.'* All cases were classified as pre-B, B, T, or early pre-B ALL according to the following criteria: pre-B if more than 10% of marrow lymphoblasts contained Cw; B if more than 10% of marrow lymphoblasts had SIg without Cp; and T if more than 40% of marrow lymphoblasts were lysed by pan-T (pT) heteroantisera (40% above control lysis by cytotoxicity testing). The early pre-B group included all patients with ALL who had complete immunophenotyping and were not classified by the above criteria, irrespective of the expression of CALLA and HLA-DR antigens. Significant expression of THY, CD3, CD4, CD8, and pan-T cell antigens (pT, CD5, CD7) was defined by cytotoxicity testing more than 40% above control. Cases were defined as CALLA-positive by J5 if J5 was greater than 40% cell lysis as compared with control, or by CALLA heteroantiserum if CALLA heteroantiserum was greater than 40%. CALLA definitions were used separately, but had strong correlation. Nearly all cases (more than 95%) were studied using both heteroantiserum and monoclonal antibodies. Event-free survival (EFS), the dependent variable of this study, is the time from achievement of a complete remission (CR) to relapse, death, or last contact, whichever occurs first. Induction failures are scored as failures at time zero.
The POG 7837 study was originally randomized, but the experimental comparison arm was closed in March 1981 after accrual objectives were achieved. Thereafter, all patients were treated identically on the LSA,L,-like regimen (Fig 1) to answer ancillary questions. Of 253 children who were confirmed as T-ALL by reference laboratory results after March 1981, 192 had complete clinical and laboratory data, permitting adequate evaluation of the impact of these parameters on outcome. The following factors were analyzed univariately for their effect on EFS: age at entry (25.0, 27.0, 29.0 and 215.0 years); WBC (210, 25, 50, and 100 x 103/pL); blast cell E-rosette formation (greater than 10,20,30, and 40%); presence or absence of a mediastinal mass, marked lymphadenopathy; French-AmericanBritish (FAB) (L1 v L2); gender; race (black v other); massive splenomegaly (below umbilicus); massive hepatomegaly (below umbilicus); hemoglobin (28 or 210 g/pL); platelet count ( r 2 5 x 1 03/wL); significant expression of acid phosphatase; and significant expression of antigens recognized by monoclonal or heterologous antibodies with specificity for HLA-DR, CD5, CD3, CD4, CD8, CALLA (by J5 and ANTI-CA), and THY antigens.
Recursive partitioning" is used to construct a treelike diagram that attempts to place patients into subsets of comparable risks. Using binary (yes/no) independent variables, partitions (branches)
are made according to the variable that has the smallest P value (which must also be less than .Ol) for all patients as the "node" (the point in the tree where a partition is to be made). Recursive partition methods also allow amalgamation (or combination) of adjacent risk groups. After each partition, groups are ranked starting from the lowest, and combined if P > .01. This procedure continues until no further partition can be achieved. The entire analysis is done in a stepwise manner, with each step attempting to partition each defined subset and amalgamate the new subsets created by the partition. This procedure differs slightly from that reported in Ciampi et all9 in
Definitions.
Study design and statistical analysis.
that amalgamation is part of our recursive process, analysis. Figure 2 tracks the recursive partitioning analysis through its tree diagram. The most significant prognostic variable was WBC count (t50 v >50 x 103/pL). This result partitioned the patients into two groups defined by WBC count. The most significant factor in the higher WBC count group was THY (positive being favorable), while within the lower WBC count group, the most significant factor was CD5 (positive being favorable). This step resulted in a total of four potential prognostic groups, two for each WBC count defined subgroup. However, two groups could be amalgamated, since there was no significant difference in outcome between the groups (WBC t 5 0 x 103/pL and CD5-) versus (WBC >50 x 103/pL and THY+). The three resultant groups were each studied for significant factors. The only subgroup revealing a significant factor (P t .01) was in the (WBC t 5 0 x 103/pL and CD5+) group (spleen). Finally, the (WBC <50% x 103/pL, CD5+, spleen+) group was amalgamated with the group (WBC 4 0 x 103/pL and CD5-) plus (WBC >50 x 103/pL and THY+), on the basis of no significant difference in outcome.
No further significant prognostic factors were uncovered within any of the three resulting groups. The outcome is defined in Figs 2 and 3. The relatively good prognosis group includes patients who (1) have a WBC count t 5 0 x 103/pL; (2) are CD5 positive; and (3) have no splenomegaly. This group has 84 patients with 4-year EFS of 66% (SE = 7%). The poor prognosis group includes patients who (1) have a WBC count >50 x 103/pL and (2) are THY negative. The poor prognosis group has 63 patients with 4-year EFS of 19% (SE = 8%). All other patients (provided that they can be classified) are considered to fall in the intermediate prognosis group, which consists of 94 patients, who have 4-year EFS of 39% (SE = 7%). The three-way logrank analysis of EFS for these three patient groups shows a significant difference (P c .001). Also, two-way analyses between the good-and intermediate-risk patients or the intermediate-versus poorrisk patients also reveal significant differences in EFS (Pc .001 and P = .007, respectively). The overall EFS within the 253 eligible patients is 43% (SE = 4%) at 4 years.
For interested readers, a forward stepwise Cox model entered only WBC, subdivided at 50 x 103/pL at P t .01.
DISCUSSION
Our results show that children with T-ALL treated with a single aggressive multimodal therapy are at widely varied risk of treatment failure, depending on clinical and laboratory parameters that are readily measured a t the time of diagnosis. This is the first large study of prognostic factors in children with T-ALL and its interpretation is facilitated by use of uniform treatment. Very little information is available regarding prognostic factors in T-ALL because it is relatively rare, often not well-identified, and usually not treated uniformly.
Similar analysis of children with non-T, non-B-cell ALL have demonstrated a wide range of clinical and biologic features that are associated with treatment outcome.'-'0 The strength of each factor in predicting outcome varies; the age of the child and extent of tumor bulk at diagnosis have consistently been among the strongest of prognostic indica- tors in these children. Therefore, it is not surprising that our univariate analysis revealed that higher WBC levels and splenomegaly, as well as older age, are associated with worse EFS in children with T-ALL. A lower hemoglobin level was associated with better treatment outcome in this study when analyzed univariately, but not in the recursive partition analysis, indicating that its independent prognostic importance is not strong. It is known that adolescents have higher hemoglobin levels compared with prepubescent children because of expected developmental changes, indicating that hemoglobin and age are interrelated factors and providing an explanation for the favorable effect of lower hemoglobin on EFS. Splenomegaly was noted to be associated with a worse prognosis in this analysis. Since it reflects increased tumor burden, its negative predictive effect on prognosis is again expected. Splenomegaly has been reported to have a similar effect on prognosis in children with non-B, ~o~-T -A L L .~. '~ The expression of CALLA on leukemic blast cells was noted to be associated with a better treatment response, as has been previously reported by us for children with T-ALL" and by a number of investigators for children with non-T, non-B-(early pre-B, and pre-B cell) ALL.25*26 The biologic explanation for this association with favorable outcome is unknown, although recent work defining the enzymatic function of CALLA27.28 may help to define its role in leukemia.
By recursive partitioning analysis, the WBC count is shown to be the strongest predictor of EFS in children with T-ALL in this study. We obtained comparable results in a much smaller study that used similar treatment.I2 However, our finding of prognostic importance of higher WBC levels (a continuous variable) extends our previous findings by demonstrating the independent and strong influence of this factor as compared with all other clinical and biologic variables measured. In this regard, the finding is consistent to that observed for children with non-B, non-T-ALL, a disease in which numerous studies have documented its strong independent predictive prognostic p~w e r .~* '~* '~ However, our findings regarding the importance of WBC count in predicting prognosis differ from those reported in this issue by Pui et ai." An age 215 years, L2 blast morphology, an abnormal karyotype and cell-surface expression of CD3 are found to infer an increased risk of treatment failure in that study. We do not have sufficient information regarding the karyotype in our study and therefore cannot evaluate this feature. Data from Pui et a1 are in general agreement with ours in regard to the negative effect of increasing age as a continuous variable. However, they report an even worse prognosis for adolescents between 15 and 21 years. Also, L2 morphology and CD3 expression on blast cells are found to be important in their study, but not in ours. Conversely, we find that blast cell expression of either L17F12 or T H Y antigen is associated with a better treatment outcome. Neither of these antibodies are directly examined in the study by Pui et al. However, we have shown that the leukemias identified by these heteroantisera are nearly the same as those recognized by CD5 or CD7, respectively; both were used in the study by Pui et al. Reasons for clear differences in our findings are speculative. The study by Pui et a1 had a higher proportion of subjects with blasts expressing CD5, age over 15 years, WBC counts over 100 x 103/pL, and treatment varied considerably, although overall treatment outcome was similar. These differences suggest important differences in the patient populations studied and may explain in part some of the differences observed. Our patient group was much larger and uniformly treated.
Our findings regarding the independent prognostic importance of expression of certain T-cell associated surface antigens and of splenomegaly have not been reported for children with T-ALL and therefore will require prospective confirmation. The association of leukemic cell expression of certain T-cell antigens recognized by the monoclonal or heteroclonal antibodies (L17F12 or anti-THY, respectively) with better EFS in subgroups of children with T-ALL is of interest, but an explanation for this association is not apparent. Both antigens are expressed relatively early during T-cell ontogeny, although they are absent a t the earliest stages of thymocyte differentiation. The THY antisera reacts with thymocytes but not peripheral T cells, and precipitates a 45,000 to 48,000 dalton common thymocyte antigen that is similar to that detected by OKT6 (CDl).'* L17F12 is an MoAb that recognizes an antigen in the CD5 cluster group which has pan-T reactivity, and used in conjunction with 3A1 (CD7), identifies virtually all pediatric cases of T-
The function of neither antigen is presently known. Discovery of the function of these molecules on normal thymocytes may provide insight into the mechanism by which these antigens confer a more favorable outlook on certain subgroups of children with T-ALL.
The relatively poor prognosis conferred by lack of CD5 expression (in the low WBC count patients), and the lack of THY expression (in the high WBC patients) would be consistent with the general notion that tumors of an immature thymic phenotype have a poor prognosis. In our own previous experience, an early stage of thymocyte differentiation had a negative impact on remission induction" with "intermediate"-stage patients (analogous to THY + patients here) and tended to have the most favorable prognosis. In other studies of non-T-ALL, antigen phenotype including expression of CALLA and myeloid antigens has also been linked to prognosis.3.25~26*29.34~35
The prognosis for children with T-ALL has improved dramatically over the past 15 years, and 40% to 70% of children are expected to survive after treatment with modern therapy.'2*35-37 This dramatic improvement in outlook for children with T-ALL has led investigators to ask why some patients with T-ALL fail treatment while others are cured. Prognostic factor analyses are useful in providing a t least partial answers to these questions. Our findings regarding the prognostic importance of both clinical and laboratory features of children with T-ALL are not surprising, since similar findings have been reported for virtually all childhood and adult neoplasms. Since only approximately 15% to 20% of children with ALL have T-cell leukemia, and approximately 2,000 cases of pediatric ALL occur annually in the US, it is apparent that accrual of sufficient subjects for studies of prognostic factors is diffi~ult.~' Very few single institutions can accrue sufficient numbers of patients to fully evaluate the independent importance of prognostic variables, and use of potentially confounding varied treatments for these patients further hinders efforts to identify prognostic factors. Also, when new factors are identified, prospective verification is recommended.
The findings from logrank and recursive partitioning analyses in this study provide a mechanism for dividing the patient population with T-ALL into groups a t strikingly varied risk of relapse in the context of therapy. Although not fully reported here, it is of interest to note that a Cox forward regression (using P -= .01 for entry) does not find any significant factor, after adjusting for WBC count > or <50 x 103/pL. Although THY and CD5 were not univariately significant, even at P = .lo, each was a powerful prognostic indicator within a WBC count defined subset. Use of easily measured clinical features, including WBC level and spleen size in conjunction with biologic features of leukemic cells, is relatively easy and has been exploited extensively for identical purposes in clinical trials for children with B-cell progenitor ALL? The information from this study, if confirmed, has potential importance in the stratification of future randomized clinical trials, since comparability of patient groups enhances the power of such trials.
Multivariate analyses require large numbers of patients to have adequate power, but are essential in establishing the independent importance of clinical and biologic variables on prognosis. Because patients with T-cell leukemia tend to have clinical features of high-risk ALL, most investigators have included such patients in therapy protocols based on clinical risk factors without regard to phenotype and, in fact, many have not even systematically identified such children. However, in current leukemia trials worldwide, most children with T-ALL are being identified and it is expected that more information regarding this phenotype of ALL will be available soon. However, stratification and treatment assignment are presently done generally without regard to immunophenotype, making evaluation of the prognostic importance of clinical or laboratory variables difficult or impossible. To address this problem, the POG has arbitrarily taken a different approach to evaluation and treatment of these children, using a single aggressive multiagent, multimodal approach. The aim of this strategy was to assess prognostic factors in T-ALL while testing proven effective therapy, modified primarily to strengthen its central nervous system prophylaxis component. This approach has permitted a detailed assessment of the relative importance of prognostic factors in T-ALL, resulting in new information which, if confirmed, could prove useful to leukemia therapists as they develop randomized trials using risk-appropriate therapy. We are currently prospectively evaluating the importance of these prognostic factors in our front-line study for children with T-ALL. Stratification for WBC count (at 50 x 103/L) is used and all other factors noted in this analysis are being further studied. The MoAbs, CD5 and CD7, have been substituted for the heteroantisera, L17F12 and THY, because they are abundant and recognize approximately the same cases. 
